



News Release

December 10, 2025

NEWS RELEASE

Eiken Chemical Co., Ltd.

Representative: Yuji Segawa, President and CEO

Securities code 4549 [TSE Prime Market]

In Vitro Diagnostic Products
Announcement of Simultaneous Launch of Three New Kits
『Loopamp® Malaria Pan Detection Kit』
『Loopamp® Malaria Pf Detection Kit』
『Loopamp® Malaria Pv Detection Kit』

Eiken Chemical Co., Ltd. (Head Office: Chiyoda-ku, Tokyo) is pleased to announce the upcoming launch of three groundbreaking in vitro diagnostic products for malaria detection. Following the PMDA (Pharmaceutical and Medical Devices Agency) approval granted on **August 21, 2025**, these products will be available starting **December 26, 2025**:

- Loopamp® Malaria Pan Detection Kit
- Loopamp® Malaria Pf Detection Kit
- Loopamp® Malaria Pv Detection Kit

Malaria is one of the world's three major infectious diseases. Globally in 2023, the number of malaria cases was estimated at 263 million, the number of deaths was estimated at 597,000 (WHO World malaria report 2024), and this disease remains a major global health threat.

Conventional diagnostic methods such as microscopy and immunochromatography may fail to detect certain cases, creating a need for technologies that offer higher sensitivity and accuracy.

Our new kits leverage the unique advantages of the LAMP technology and, when used with our “Real-Time Turbidimeter LoopampEXIA®,” enable highly sensitive detection of malaria parasites from nucleic acids extracted from specimens in just 40 minutes. Including sample pretreatment, results can be reported within one hour.

Sample pretreatment (nucleic acid extraction and purification) can be easily performed using the “**Loopamp PURE DNA Extraction Kit**”, which is also employed with our Loopamp MTBC Detection Kit, allowing for simplified nucleic acid extraction from whole blood.

Furthermore, by achieving detection of DNA from as little as a single parasite through the high sensitivity of LAMP-based genetic testing, these kits not only enable prompt initiation of appropriate treatment but also contribute to identifying asymptomatic carriers, supporting early intervention, and preventing the spread of infection.

Eiken Chemical remains committed to delivering innovative diagnostic solutions that enhance healthcare quality and accessibility globally. These products offer a powerful tool in the fight against malaria, contributing to improved patient outcomes toward **Zero Malaria** and global health initiatives.

For more information about these products, please visit our website:

Contact details

Sustainability Department

Eiken Chemical Co., Ltd.

TEL: +81-3-5846-3305, e-mail: koho@eiken.co.jp

<https://www.eiken.co.jp/en>